Loading...
Not only are polygenic risk scores (PRSs) being used for prediction of disease risk, but there is also growing interest in their use for predicting treatment response. These scores quantify the aggregate effect of many single nucleotide polymorphisms (SNPs) within the genome.
Investigators made use of the UK Biobank to further investigate a polygenic response predictor (PRP) for beta-blocker therapy in people with heart failure and reduced ejection fraction. The PRP had identified 25% of the patients who had a substantial survival advantage with beta-blocker therapy and 75% with little benefit. This PRP was based on 44 loci in the genome. They focused on white patients (because this was a validation study and the prior study had included peo…